CJC-1295: identity, hormone studies and evidence limits
CJC-1295 was developed as a long-acting analogue of growth-hormone-releasing hormone. Early human studies demonstrated changes in growth hormone and IGF-1, not proven anti-aging, fat-loss or muscle-performance outcomes. Exact identity is essential because the CJC name is used inconsistently across product listings.
Identity and formulation
The original research compound incorporates an albumin-binding modification. A material described as CJC without DAC should not inherit the long half-life or clinical results of that modified compound.
Growth-hormone-releasing hormone acts on secretion; it is not growth hormone itself. A biomarker response to a secretagogue does not establish equivalence to a licensed growth-hormone treatment.
What the studies show
The selected studies support pharmacological activity of the original long-acting research construct. They do not answer whether a person becomes stronger, loses fat or ages more slowly. A separate CJC-DAC article explains persistence and exposure in more detail.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
Chemical development, cultured rat pituitary cells and rat experiments Reading scope: PubMed abstract and bibliographic record; not full-text review |
The investigators characterized a modified GHRH analogue designed to bind albumin and remain active longer. | This establishes the identity and preclinical rationale of the modified construct, not clinical benefit for every CJC-named product. |
| Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Two randomized placebo-controlled ascending-exposure trials in healthy adults Reading scope: PubMed abstract and bibliographic record; not full-text review |
The long-acting compound increased circulating GH and IGF-1 over the monitored period. | Hormone concentrations were the key outcomes; the trials did not demonstrate improved body composition, strength or longevity. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
A rise in a hormone is evidence that a biological pathway was affected. Whether that change produces a net health benefit requires a separate clinical question and appropriate endpoints.
Healthy volunteers are not patients with confirmed growth-hormone deficiency. Different underlying pituitary function can change what a secretion-stimulating intervention could do.
FDA’s December 2024 assessment highlighted inconsistent naming and incompletely specified salt forms in the clinical literature. Matching the complete molecular construct is more reliable than relying on a product nickname.
Safety context
The early paper’s report of no serious adverse reactions does not mean no adverse events occurred. FDA’s dated assessment describes injection-site reactions and systemic symptoms in the underlying studies.
Short exposures in healthy adults do not establish long-term safety or the safety of a differently modified preparation.
Study exposure and units
Identify the actual construct before comparing any exposure. A sequence without the albumin-binding modification and one with it cannot be treated as the same pharmacokinetic material.
A study schedule in healthy volunteers is not a personal anti-aging regimen. Duration of hormone elevation also differs from how long a clinically meaningful benefit lasts.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Ask whether the full sequence, terminal modifications, albumin-binding group and salt are specified. A CJC label alone leaves the central identity issue unresolved.
A chromatography purity result without adequate identity characterization does not establish which CJC-related substance was tested.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Does CJC-1295 research prove muscle growth or anti-aging benefit?
The key trials here measured GH and IGF-1. Those are intermediate biological outcomes, not direct evidence of greater strength, longer life or a clinically meaningful fat-loss result.
Can a no-DAC listing use the original study’s half-life?
No. The albumin-binding modification is central to the original long-acting construct. A differently specified molecule needs its own evidence.
Sources
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. (PubMed abstract and bibliographic record; not full-text review)
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. (PubMed abstract and bibliographic record; not full-text review)
- FDA December 2024 CJC-1295 assessment in PCAC transcript (Official transcript, CJC characterization and clinical-safety sections)